Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Factor VIII inhibitors seen in some patient subgroups, not others

Gangadharan B et al. ASH 2018, Poster 3774

Key clinical point: Researchers identified four distinct patient subgroups in severe hemophilia A.

Major finding: Two of the subgroups had Factor VIII inhibitors and two of the subgroups did not.

Study details: The study included 23 infants with previously untreated severe hemophilia A who received 50 days’ exposure to FVIII infusions.

Disclosures: The study is funded by Baxalta, a part of Shire. Dr. Gangadharan is employed by Shire and other authors reported financial disclosures related to the study sponsor.

Read the article here.


Gangadharan B et al. ASH 2018, Poster 3774.